Company intelligence / Profile preview

Global BIO Impact Fund

California, United States

Ownership: Private
Development stage: Other

Overview

Global BIO Impact Fund is a venture capital firm, not a biotech operating company, focused on investing in disruptive life science technologies for financial returns and positive impact. It targets early-stage biotech innovations, exemplified by its $45M commitment to BioAtla's cancer antibody therapeutics. In 2016, it partnered with Cavendish Global to launch Cavendish Impact Capital Life Science Fund, managed under its leadership. No recent activity post-2016 is evident in available sources; status as active is inferred from context as no closure noted.

Therapeutic areas: OncologyOther
Modalities: Antibody Therapies
Industry: Investors

Partnerships

Cavendish GlobalCavendish Impact CapitalBioAtlaPfizer (via portfolio)Beijing Sinobioway Group (via portfolio)

Beyond the preview

Go deeper on Global BIO Impact Fund.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Global BIO Impact Fund.

Explore the full profile